• Company
• Clinical trial failures…novel PD drugs face challenges
• by Son, Hyung-Min May 23, 2024 05:48am

• Company
• Leclaza’s sales soar with reimbursement expansion
• by Chon, Seung-Hyun May 23, 2024 05:48am

• Policy
• 4 Pharmas make bid into low-dose statin combo drug mkt
• by Lee, Tak-Sun May 22, 2024 05:47am

• Company
• Oral renal anemia drug meets reimb listing terms
• by Nho, Byung Chul May 22, 2024 05:47am

• Company
• MSD applies for Welireg’s reimbursement in Korea
• by Eo, Yun-Ho May 22, 2024 05:47am

• Company
• FDA approves Samsung and Biocon’s Eylea biosimilars
• by Son, Hyung-Min May 22, 2024 05:47am

• Policy
• Forxiga to maintain upper limit price until Korean mkt exit
• by Lee, Tak-Sun May 22, 2024 05:47am

• Company
• FDA approval delayed and retry…what’s 'Rivoceranib'?
• by Son, Hyung-Min May 21, 2024 05:56am

• Company
• Flu drug market enjoys rise for 6 consecutive quarters
• by Chon, Seung-Hyun May 21, 2024 05:56am

• Company
• Series of drug patent expiries change ₩250B DOAC mkt
• by Moon, sung-ho May 21, 2024 05:55am